A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.
about
Systemic delivery of oncolytic viruses: hopes and hurdlesPromising oncolytic agents for metastatic breast cancer treatmentNDV-D90 suppresses growth of gastric cancer and cancer-related vascularizationGene therapy progress and prospects cancer: oncolytic viruses.Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors.Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Safety and clinical usage of newcastle disease virus in cancer therapyOncolysis by paramyxoviruses: preclinical and clinical studies.Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virusProinflammatory response induced by Newcastle disease virus in tumor and normal cells.Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.Trial watch: Oncolytic viruses for cancer therapyOptimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses.Oncolytic viral therapy of malignant gliomaNew perspectives in cancer virotherapy: bringing the immune system into play.Use of attenuated paramyxoviruses for cancer therapy.Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and HostOncolytic viruses: a new class of immunotherapy drugs.Evaluation of the oncolytic potential of R2B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620).Current status of clinical trials assessing oncolytic virus therapy for urological cancers.Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma.Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.Viral persistence in colorectal cancer cells infected by Newcastle disease virus.Oncolytic viruses: emerging options for the treatment of breast cancer.Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.Isolation of avian paramyxovirus 1 from a patient with a lethal case of pneumoniaMaraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats.Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.A Comparative Safety Profile Assessment of Oncolytic Virus Therapy Based on Clinical Trials.Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.
P2860
Q21284969-ECB0E632-8DA8-45FC-8EEB-76C7A533E740Q26830620-C83286F5-21A4-4C7C-9983-BE184532BF2AQ33798447-DDEDABF5-8610-45FA-A54A-80528F5F71F8Q34770611-9DE440BF-6862-4239-9360-A074A573AF31Q35111983-C2ABEB0D-C3F4-41D1-B970-BF97A768826BQ35224606-FBBF16B4-E7A3-475F-A1D0-B0322A6DE41DQ35498222-1C2CF39B-7EC2-4E4C-8106-A6377044B926Q35861933-D8B36373-C7C6-4358-8B06-8267D2479B53Q36039304-24C8263A-E41C-408B-B956-3E279D917B68Q36308045-BF96B7A3-7765-4397-A434-BF3AD0BF1DDCQ36507259-C49406C3-E196-4A87-8053-54DB60CDBC59Q37028023-6DA05DCD-EF1A-4D6E-AD95-744219170075Q37033299-241231E3-68C0-4E9B-9706-1B5E45A4D673Q37533665-8D1BBE4D-09A1-4183-8287-A3232F635B91Q37773253-1B43D717-167E-483B-A1E1-5C9BC32F7CC0Q37810599-BC43F15F-52E3-4AC4-BE41-78490E8F2AE3Q37990940-D3069281-2990-4840-A8D0-CFBD93454610Q38264652-6DA1CDBF-9FD9-4079-A692-17E8E37FAA5BQ38369289-6135F14D-00C6-49F7-8BE0-BCAA9A111216Q38577450-79FA37C4-1718-4A0F-8F25-783DC91A449DQ38701351-E39B787C-C543-416E-9FCE-44A0420373AEQ38741837-C51B5084-302B-4781-80CE-70AA177BEC95Q38886736-707F6C40-E5A7-449B-96AE-CE49CA383069Q38953230-BC965EF1-379E-4723-BFAD-A96B32B3CCEEQ38989363-B1493437-1E13-45A0-A41E-84C6480E02A3Q39129326-925CCF98-10B3-42D7-BCB6-99F4671172F3Q40024329-252B10CB-85AE-4717-89ED-9BBB8463E61FQ41168464-3EAED0DF-2C68-4B69-91EA-033B3F75DFDEQ41410427-DA4E0EAF-E3A9-46E5-B4B5-63C04B8505E8Q41744540-BD2CAB4E-BF3F-4CAD-A2BE-E94E97C359F2Q41904204-2F85D637-2C7E-44A1-B2B7-6971B18EB39CQ45324726-66BEBD35-F380-4044-9601-B27645ADC3ECQ54241184-73C74C2F-8967-4951-AECE-CB2B617A8C06Q54461045-909A9E8E-A8EF-46F0-9CC2-3018D3CAAC42Q54967512-CA6B9200-5A9A-4B6C-B934-F238ABAC49A9
P2860
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A phase 1 clinical study of in ...... sing two-step desensitization.
@ast
A phase 1 clinical study of in ...... sing two-step desensitization.
@en
type
label
A phase 1 clinical study of in ...... sing two-step desensitization.
@ast
A phase 1 clinical study of in ...... sing two-step desensitization.
@en
prefLabel
A phase 1 clinical study of in ...... sing two-step desensitization.
@ast
A phase 1 clinical study of in ...... sing two-step desensitization.
@en
P2093
P1476
A phase 1 clinical study of in ...... sing two-step desensitization.
@en
P2093
Harold L Atkins
James D O'Neil
Joanne Roach
M Scot Roberts
Michael K Bamat
Robert M Lorence
Scott A Laurie
William S Groene
P304
P356
10.1158/1078-0432.CCR-05-2038
P407
P50
P577
2006-04-01T00:00:00Z